Skip to content
← Full study record

NCT00536575 · MORE INFO

Limitations, agreements, and source contact

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients · Source last updated 2013-02-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The 15% response rate was substantially lower than the designed rate of 60% for this trial. Coupled with the influx of new compounds for the treatment of multiple myeloma it was decided that this study should be closed early.
point Of Contact
email
asksarah@scresearch.net
organization
Sarah Cannon Research Institute
phone
1-877-691-7274
title
John Hainsworth, MD
Complete source fields
certain Agreement
other Details
The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The 15% response rate was substantially lower than the designed rate of 60% for this trial. Coupled with the influx of new compounds for the treatment of multiple myeloma it was decided that this study should be closed early.
point Of Contact
email
asksarah@scresearch.net
organization
Sarah Cannon Research Institute
phone
1-877-691-7274
title
John Hainsworth, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice